On April 12, 2019, a new paper, "Effective Vaccination against Middle East Respiratory Syndrome Corona-virus," that focuses on the threat of emerging infectious pathogens and methods to develop vaccines to combat has been published. Diving into further details into pathogens such as Middle East respiratory syndrome corona-virus (MERS-CoV), it is important to understand the history of the disease, MERS.

According to the World Health Organization, MERS was first identified in Saudi Arabia in 2012. The symptoms range from fever and possibly pneumonia which may not alert the patient or motivate the patient into getting further tests. Separately, the MERS CoV infections are so far asymptomatic which means any clinical symptoms may not be present but can be tested positive through a simple laboratory exam. A total of about 35% of patients who have MERS have died.

The paper referenced earlier focuses on creating effective vaccination against MERS-CoV which goes into detail of a nano-particle vaccine that delivers antigens and STING agonists. Through this process, the tests conducted with such nano-particle vaccine candidates have shown a positive response to combating the MERS-CoV. RheoSense's viscometer, microVISC™, was used during this study which can present a number of benefits including:

Working with small samples - assisting in the use of nano-particle vaccines enabling small sample requirements for testing

Portable - can be used in essentially any setting, battery charge enables you to 100 measurements

Quick measurements (less than one minute) - enabling you to get quick and fast measurements especially when working with various vaccines and/or even blood

<< View the full list of publications that use RheoSense technology to help advance hundreds scientists and researchers all over the globe